# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Charles Zhu maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $16 to...
Barclays analyst Peter Lawson maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and lowers the price target from ...
Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now...
Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target fro...
TNG348 was being studied in a phase 1/2 clinical trial evaluating safety, pharmacokinetics, pharmacodynamics and efficacy as a ...
HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $17 price ...